AMCP Format for Formulary Submissions
The US managed-care industry standard for the structure and content of evidence dossiers submitted by pharmaceutical and biologic manufacturers to support formulary consideration by health plans and pharmacy benefit managers. Version 5.0 (2024) is the current edition. It sets expectations for clinical, economic, and patient-reported outcomes evidence — the primary document payers request when evaluating a new product for formulary placement in the United States.
What it is
— The AMCP Format for Formulary Submissions (AMCP Format) is the de facto US payer dossier standard published and maintained by the Academy of Managed Care Pharmacy (AMCP). First issued in 2000 and now in its fifth edition (Version 5.0, 2024), it specifies the content and organisation of a comprehensive evidence package — a "formulary dossier" — that manufacturers prepare when seeking formulary consideration from US managed care organisations, pharmacy benefit managers (PBMs), and integrated delivery networks (IDNs). Unlike HTA submissions in Europe (NICE, G-BA, HAS, JCA), the AMCP Format is not a regulatory requirement but an industry convention: adoption is voluntary, yet the document has become the default request from US payer pharmacy and therapeutics (P&T) committees. Version 5.0 updates the structure to reflect the expanded role of real-world evidence, patient-centric outcomes, health equity considerations, and digital/cell-and-gene-therapy product types. The dossier is organised around a product Section 1 (product information: indication, mechanism, dosing), Section 2 (clinical evidence: pivotal trials, subgroup data, indirect comparisons, RWE), Section 3 (economic and outcomes evidence: budget impact, cost-effectiveness models, HEOR dossier), and Section 4 (product value and patient-reported outcomes), plus a supporting appendix. The format does not adjudicate evidence quality — it defines what evidence to organise and present, leaving P&T committees to judge adequacy.
When to use
— The AMCP Format governs US payer dossier preparation. Apply it when: a manufacturer is seeking formulary placement, preferred tier status, or step-edit removal from a US health plan, PBM, or integrated delivery network; when a payer's medical or pharmacy director has requested an evidence dossier for a P&T committee review; or when a HEOR, market access, or medical affairs team needs a standardised framework for assembling and organising the full clinical-economic evidence package for a US submission. Decision rule: for US managed-care formulary submissions, use the AMCP Format (version 5.0 for new submissions); for European HTA submissions (Germany, France, UK, EU JCA), the relevant national or regional guidance applies (G-BA AMNOG, HAS CEESP, NICE reference case, EU HTA JCA regulation); for value-based contracting or payer engagement outside a formal dossier, the AMCP Format sections can still structure the evidence narrative but are not used verbatim. The AMCP Format complements rather than replaces clinical study reports — it is an evidence organisation standard, not a study-conduct or reporting guideline.
What it requires (checklist domains)
— The AMCP Format enforces a structured dossier with these key components that P&T reviewers expect: Section 1 — Product information: FDA-approved labelling (prescribing information), mechanism of action, proposed formulary tier, and any REMS requirements. Section 2 — Clinical evidence: (a) Pivotal controlled trial data (efficacy, safety, subgroup analyses, and head-to-head comparisons where available); (b) Indirect treatment comparisons and network meta-analyses for placing the product relative to formulary alternatives when no head-to- head trials exist (see ISPOR Indirect Comparisons guideline); (c) Real-world evidence — claims, EHR, registry, or patient-reported outcomes data demonstrating effectiveness and safety in broader or plan-specific populations, a rapidly growing dossier section given FDA's increased emphasis on RWE; (d) disease burden and unmet need in the target managed-care population. Section 3 — Economic and outcomes evidence: a budget impact model (BIM) customisable to a plan's patient population and cost structure; a cost-effectiveness model (cost per QALY or cost per outcome); supporting HEOR analyses (adherence, resource utilisation, productivity). Section 4 — Value summary and PROs: patient-reported outcomes evidence (instruments, minimally important differences) and a value summary narrative. Appendix: full clinical study reports, model technical reports, and supporting literature. Version 5.0 adds explicit sections on health equity, digital therapeutics, and cell and gene therapies to reflect product-type expansion.
When NOT to use — limitations and common misapplications
— The AMCP Format is a US managed-care convention; it does not substitute for European HTA dossier requirements, FDA regulatory submissions, or NICE technology appraisals. Common misapplications: (1) Confusing the AMCP dossier with a value file — a value file is an abbreviated sales-aid document for account managers; the AMCP Format is a comprehensive P&T evidence package requested by medical and pharmacy directors, not a marketing leave-behind. (2) Treating compliance with the format as evidence of quality — the AMCP Format organises content; it does not set the evidentiary bar. A dossier can follow the template exactly while relying on a poorly designed indirect comparison or an unvalidated claims outcome algorithm; P&T reviewers use tools like ISPOR Indirect Comparisons, GRADE, or GRACE to appraise individual sections. (3) Ignoring the RWE sections — many manufacturers still treat Sections 2c and the economic sections as optional; US payers are increasingly requesting RWE to understand real-world effectiveness and adherence in their own populations. (4) Using an outdated version — Versions 3.0 (2010) and 4.0 (2016) are no longer the current standard; Version 5.0 (2024) updates the structure for modern product types and evidence expectations. (5) Applying the AMCP Format to EU markets — European JCA, NICE, and national HTA bodies have their own submission requirements that differ substantially in PICO scope, comparator selection, and economic reference-case assumptions.
How it maps to this catalog
— Each AMCP Format section draws on a cluster of methods-catalog concepts for its evidence. Section 2 clinical evidence on RWE effectiveness and safety relies on the core pharmacoepidemiology concepts: active-comparator-new-user and target-trial-emulation (rigorous observational design), propensity-score-methods-psm-iptw (confounding control in claims/EHR studies), and fit-for-purpose-data-assessment-rwe (confirming the data source is adequate for the managed-care population). Outcome validity — a common P&T concern in claims-based RWE — is addressed by claims-outcome-algorithm-ppv-sensitivity-rwe and diagnosis-phenotype-algorithm-1ip-2op-time-window-rwe. Section 2b indirect comparisons are governed by ispor-indirect (the ISPOR Indirect Treatment Comparisons guideline in this catalog) and prisma-nma (PRISMA-NMA for the systematic review underpinning the network). Section 3 economic models follow ispor-modeling (good practices for economic modeling) and ispor-bia (budget impact analysis). Patient-reported outcomes in Section 4 are appraised via cosmin-criteria, cosmin-reporting, and isoqol-standards. The full evidence hierarchy that P&T committees apply to appraise AMCP dossier submissions can be structured using grade and grace for observational evidence quality. The US payer-specific design choices underlying a strong AMCP dossier RWE section are also informed by ispor-suitability (RWD suitability framework) and the fda-rwe-framework and fda-rwd-ehr-claims guidances (increasingly cited by payers as benchmarks for RWE credibility).